- Home
- WKC vs DNTH Comparison
WKC vs DNTH Comparison
Compare WKC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKC
- DNTH
- Stock Information
- Founded
- WKC 1984
- DNTH 2015
- Country
- WKC United States
- DNTH United States
- Employees
- WKC N/A
- DNTH N/A
- Industry
- WKC Oil Refining/Marketing
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- WKC Energy
- DNTH Health Care
- Exchange
- WKC Nasdaq
- DNTH Nasdaq
- Market Cap
- WKC 1.4B
- DNTH 1.4B
- IPO Year
- WKC N/A
- DNTH N/A
- Fundamental
- Price
- WKC $25.98
- DNTH $32.75
- Analyst Decision
- WKC Hold
- DNTH Strong Buy
- Analyst Count
- WKC 4
- DNTH 11
- Target Price
- WKC $28.75
- DNTH $65.22
- AVG Volume (30 Days)
- WKC 551.2K
- DNTH 516.1K
- Earning Date
- WKC 10-23-2025
- DNTH 11-07-2025
- Dividend Yield
- WKC 3.09%
- DNTH N/A
- EPS Growth
- WKC N/A
- DNTH N/A
- EPS
- WKC N/A
- DNTH N/A
- Revenue
- WKC $37,648,100,000.00
- DNTH $4,854,000.00
- Revenue This Year
- WKC N/A
- DNTH N/A
- Revenue Next Year
- WKC $2.16
- DNTH N/A
- P/E Ratio
- WKC N/A
- DNTH N/A
- Revenue Growth
- WKC N/A
- DNTH 17.87
- 52 Week Low
- WKC $22.71
- DNTH $13.37
- 52 Week High
- WKC $31.54
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- WKC 52.50
- DNTH 41.99
- Support Level
- WKC $25.55
- DNTH $32.28
- Resistance Level
- WKC $26.19
- DNTH $35.40
- Average True Range (ATR)
- WKC 0.56
- DNTH 1.57
- MACD
- WKC 0.06
- DNTH -0.26
- Stochastic Oscillator
- WKC 59.06
- DNTH 9.00
About WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.